X

Trial Profile

Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Botaretigene sparoparvovec (Primary)
Indications Retinitis pigmentosa
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Janssen Research & Development; Janssen-Cilag; MeiraGTx

Most Recent Events

01 Feb 2024 Planned End Date changed from 20 Sep 2029 to 19 Dec 2029.
23 Jan 2024 Status changed from recruiting to active, no longer recruiting.
07 Nov 2023 Planned number of patients changed from 96 to 97.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com